In Reply Pang et al raised the concern of immune thrombocytopenia being neglected as an adverse event associated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors in clinical trials. This perceived oversight may have stemmed from the low incidence of thrombocytopenia reported in clinical trials of PD-1 and PD-L1 inhibitors, the challenge in diagnosing immune thrombocytopenia, and the potential life-threatening severity of immune thrombocytopenia in rare cases.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wang Y, Yang F, Wang ML. Immune Thrombocytopenia—A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials—In Reply. JAMA Oncol. 2019;5(11):1641–1642. doi:10.1001/jamaoncol.2019.3608
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.